Mekinist (trametinib) is a prescription drug that’s used to treat certain types of cancers and tumors. Mekinist comes as a powder that a pharmacist mixes into an oral solution and an oral tablet.

Mekinist (trametinib) is a prescription drug that treats specific cancers, including skin, lung, thyroid, and brain. Mekinist’s cost may depend on your dosage, whether you have health insurance ...

Results from the COMBI-d study of 423 patients found the estimated three-year survival rate to be 44% for patients receiving the combination of Tafinlar + Mekinist (95% CI, 36.4%-50.5% ...

Tafinlar and Mekinist combination therapy shows efficacy in glioma treatment for both pediatric and adult patients, with higher response rates in pediatric cases. Objective response rates were 53% for ...

Basel, April 3, 2017 - Novartis today announced the European Commission has approved Tafinlar ® (dabrafenib) in combination with Mekinist ® (trametinib) for the treatment of patients with BRAF ...

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma. Tafinlar (dabrafenib) plus Mekinist (trametinib) continued to be efficacious ...

Trametinib 4.7mg; per bottle; pwd for oral soln after reconstitution; strawberry flavored. In combination with dabrafenib for the treatment of pediatric patients with low-grade glioma (LGG) with a ...

Researchers reported that 34% (95% CI: 30-38%) of all patients in the pooled analysis who were treated with Tafinlar + Mekinist survived at five years 1. Study authors also reported on ...

The Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K ...

It is the generic version of Mekinist, a branded product developed by Novartis Pharma AG (NYSE:NVS). As part of the deal, Hikma also entered into a commercial agreement with Novugen under which it ...

From today many with stage 3B to stage 4 melanoma will now have wider access to Keytruda and the branded drug Tafinlar and Mekinist. Melanoma New Zealand Chief executive Andrea Newland says this ...